Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials

被引:7
作者
Kornstein, Susan [1 ]
Chang, Cheng-Tao [2 ]
Gommoll, Carl P. [3 ]
Edwards, John [3 ]
机构
[1] Virginia Commonwealth Univ, Dept Psychiat, POB 980319, Richmond, VA 23298 USA
[2] Allergan, Dept Biostat, Irvine, CA USA
[3] Allergan, Dept Clin Dev, Madison, NJ USA
关键词
antidepressant; demographics; major depressive disorder; symptom severity; vilazodone; STAR-ASTERISK-D; ANTIDEPRESSANT RESPONSE; CLINICAL-TRIALS; META-REGRESSION; RATING-SCALE; PRIMARY-CARE; OUTCOMES; METAANALYSIS; RELEVANT; ILLNESS;
D O I
10.1097/YIC.0000000000000217
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of antidepressants to treat major depressive disorder (MDD) varies by patient characteristics. This post-hoc analysis evaluated the effects of vilazodone across patient subgroups in adults with MDD. Data were pooled from four trials of vilazodone (NCT00285376, NCT00683592, NCT01473394, and NCT01473381). Mean change from baseline to week 8 in Montgomery-angstrom sberg Depression Rating Scale (MADRS) total score, MADRS response (50% total score improvement), and MADRS remission (total score10) were analyzed in the pooled intent-to-treat population (vilazodone=1254, placebo=964) and in subgroups of patients categorized by sex, age, MDD duration, recurrent episodes, baseline MADRS total score, and current episode duration. MADRS total score improvement was significantly greater with vilazodone versus placebo in the intent-to-treat population and in all patient subgroups (P<0.001). MADRS response and remission rates significantly separated from placebo (P<0.05) regardless of age, sex, MDD duration, recurrent MDD, and baseline symptom severity [except remission in patients with very severe baseline symptoms (MADRS score35)] and in patients with a shorter current episode duration (12 months). Despite the limitations associated with analyzing uncommon outcomes (e.g. MADRS remission) in small subgroups, vilazodone was an effective treatment in multiple patient populations, including those where reduced efficacy has previously been reported: males, older individuals, patients with a longer duration of MDD, and patients with recurrent depression.
引用
收藏
页码:217 / 223
页数:7
相关论文
共 29 条
  • [1] [Anonymous], 2010, PRACTICE GUIDELINE T
  • [2] Objective: remission of depression in primary care The Oreon Study
    Ansseau, Marc
    Demyttenaere, Koen
    Heyrman, Jan
    Migeotte, Andre
    Leyman, Sophie
    Mignon, Annick
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 (03) : 169 - 176
  • [3] APA A.P. A., 2000, Diagnostic and statistical manual of mental disorders: DSM-IV, V4th
  • [4] When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed
    Citrome, L.
    Ketter, T. A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (05) : 407 - 411
  • [5] Efficacy and Safety of Vilazodone in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
    Croft, Harry A.
    Pomara, Nunzio
    Gommoll, Carl
    Chen, Dalei
    Nunez, Rene
    Mathews, Maju
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (11) : E1291 - E1298
  • [6] Population-based study of first onset and chronicity in major depressive disorder
    Eaton, William W.
    Shao, Huibo
    Nestadt, Gerald
    Lee, Ben Hochang
    Bienvenu, O. Joseph
    Zandi, Peter
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2008, 65 (05) : 513 - 520
  • [7] A RATING SCALE FOR DEPRESSION
    HAMILTON, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1960, 23 (01) : 56 - 62
  • [8] Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs
    Hirschfeld, RMA
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (05) : 326 - 335
  • [9] Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression
    Howland, Robert H.
    Wilson, Michael G.
    Kornstein, Susan G.
    Clayton, Anita H.
    Trivedi, Madhukar H.
    Wohlreich, Madelaine M.
    Fava, Maurizio
    [J]. ANNALS OF CLINICAL PSYCHIATRY, 2008, 20 (04) : 209 - 218
  • [10] Pharmacological treatment of severely depressed patients: A meta-analysis comparing efficacy of mirtazapine and amitriptyline
    Kasper, S
    Zivkov, M
    Roes, KCB
    Pols, AG
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) : 115 - 124